Winer pointed out the mice and the human volunteers were all male, so it's not clear if these findings are applicable to women.
Winer also noted that anti-CD20 is not benign. It dampens the immune system and can cause significant side effects, so he said he wasn't sure if it would ever be used for type 2 diabetes because other treatments are available.
Dr. David Kendall, chief scientific and medical officer for the American Diabetes Association, agreed.
"This doesn't change our current approach to type 2 diabetes therapy, but it's important to understand that type 2 has multiple contributors to its onset. For some people, it may be an immune component, and if it is, we should be able to develop some better therapies," Kendall said.
"People with type 2 diabetes are often blamed for bringing the disease on, but it's a combination of genetic and physiological factors exposed to a certain environment. And, this study points out what may be another important biologic factor," he added.
To learn more about type 2 diabetes, visit the American Diabetes Association.
Copyright © 2011 HealthDay. All rights reserved.